Treatment of vitamin D deficiency in CKD patients with ergocalciferol: Are current K/DOQI treatment guidelines adequate?

Clinical Nephrology

Volumn 73, Issue 4, 2010, Pages 276-285

  Qunibi, W Y ^a   Abdellatif, A ^a   Sankar, S ^a   Hamdan, Z ^a   Lin, F Y ^a   Ingle, J ^a   Cadena, A ^a   Gelfond, J ^a   Kasinath, B ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

25 hydroxyvitamin D; Calcitriol; Chronic kidney disease; Parathyroid hormone; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ERGOCALCIFEROL; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPARATHYROIDISM; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PRACTICE GUIDELINE; RECOMMENDED DRUG DOSE; TREATMENT DURATION; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 77950793603     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP73276     Document Type: Article

References (47)

1. Al-Aly Z, Qazi RA, Gonzalez EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. AJKD. 2007; 50: 59-68. (Pubitemid 46962851)
2. Andress D, CoyneDW, Kalantar-Zadeh K, Molitch ME, Zangeneh F, Sprague SM. Management of secondary hyperparathyroidism in Stages 3 and 4 chronic kidney disease. Endocrine Practice. 2008; 14: 18-27.
3. Andress DL. Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation. Kidney Int. 2006; 69: 33-43.
4. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004; 89: 5387-5391.
5. Autier P, Gandini S. Vitamin D supplementation and total mortality:Ameta-analysis of randomized controlled trials. Arch Intern Med. 2007; 10: 1730-1737. (Pubitemid 47403059)
6. Bianchi ML, Colantonio G, Campanini F, Rossi R, Valenti G, Ortolani S, Buccianti G. Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant. 1994; 9: 1595-1599. (Pubitemid 24344776)
7. Binkley N, Novotny R, Krueger D, Kawahara T, Daida YG, Lensmeyer G, Hollis BW, Drezner MK. Low vitamin D status despite abundant sun exposure. J ClinEndocrinolMetab. 2007; 92: 2130-2135. (Pubitemid 46997111)
8. Binkley N, Krueger D, Cowgill CS, Plum l, Lake E, Hansen KE, DeLuca HF, Drezner MK. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab. 2004; 89: 3152-3157. (Pubitemid 38951877)
9. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitaminD supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005; 11; 293: 2257-2264. (Pubitemid 40629192)
10. Boudville NC, Hodsman AB. Renal function and 25- hydroxyvitaminDconcentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant. 2006; 21: 2621-2624. (Pubitemid 44644541)
11. Brumbaugh PF, Haussler MR. 1, 25-dihydroxycholecalciferol receptors in intestine. I. Association of 1, 25-dihydroxycholecalciferol with intestinal mucosa chromatin. J Biol Chem. 1974; 249: 1251-1257.
12. 3: Humoral and histomorphometric results.Miner Electrolyte Metab. 1986; 12: 375-382. (Pubitemid 17002647)
13. Deville J, Thorp M, Tobin L, Gray E, Johnson ES, Smith DH. Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology. 2006; 11: 555-559. (Pubitemid 44951240)
14. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005; 289: 8-28.
15. Glendenning P, Noble JM, Taranto M, Musk AA, McGuiness M, Goldswain PR, Fraser WD, Vasikaran SD. Issues of methodology, standardization andmetabolite recognition for 25-hydroxyvitaminD when comparing the DiaSorin radioimmunoassay and the Nichols Advantage automated chemiluminescence protein-binding assay in hip fracture cases. Ann Clin Biochem. 2003; 40: 546-551. (Pubitemid 37152208)
16. Glendenning P, Taranto M, Noble JM, Musk AA, Hammond C, Goldswain PR, FraserWD, Vasikaran SD. Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays. Ann Clin Biochem. 2006; 43: 23-30. (Pubitemid 43105054)
17. Gonzalez EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004; 24: 503-510. (Pubitemid 39656665)
18. Hamdan Z, Abdellatif A, Mididdodi R, Perez A, Rincon-Choles H, KasinathK, Qunibi W. Prevalence of vitamin D insufficiency/deficiency in patients with CKD. Presented at the NKF meeting. Chicago. April 2006. Am J Kidney Dis. 2006; 47: 1-18.
19. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357: 266-281.
20. Jones G, Byford V, West S, Masuda S, Ibrahim G, Kaufmann M, Knutson JC, Strugnell S, Mehta R. Hepatic activation and inactivation of clinically-relevant vitamin D analogs and prodrugs. Anticancer Res. 2006; 26: 2589-2595. (Pubitemid 44155539)
21. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy S, Kilpatrick RD, Shinaberger CS, McAllister CJ, BudoffMJ, Salusky IB, Kopple JD. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70: 771-780. (Pubitemid 44215354)
22. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009; 76 (Suppl): 1-130.
23. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008; 168: 397-403. (Pubitemid 351350586)
24. Krall EA, Sahyoun N, Tannenbaum S, Dallal GE, Dawson-Hughes B. Effects of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women. N Engl J Med. 1989; 321: 1777-1783. (Pubitemid 20015570)
25. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM. Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005; 45: 1026-1033. (Pubitemid 40806515)
26. Lafage MH, Combe C, Fournier A, Aparicio M. Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int. 1992; 42: 1217-1225.
27. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71: 31-38. (Pubitemid 44967731)
28. Levin A, Li YC. Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease? Kidney Int. 2005; 68: 1973-1981. (Pubitemid 43117772)
29. Lips P, Chapuy MC, Dawson-Hughes B, PolsHAP, Holick MF. An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporosis Int. 1999; 9: 394-397. (Pubitemid 29231730)
30. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, Felsenfeld A, Levine B, Mehrotra R, Norris K. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States. Data from the third National Health and Nutrition Examination Survey. Arch Int Med. 2007; 167: 1159-1165.
31. 3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology. 2005; 146: 825-834. (Pubitemid 40129840)
32. McKenna MJ, Freany R. Secondary hyperparathyroidism in the elderly: means to defining hypovitaminosis D. Osteoporosis Int. 1998; 8(Suppl): 3-6.
33. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008; 168: 1629-1637.
34. 3. Arch Biochem Biophys. 1979; 197: 90-95.
35. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Suppl): 1-201.
36. Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab. 1988; 67: 929-936.
37. Phinney KW. Development of a standard reference material for vitamin D in serum. Am J Clin Nutr 2008; 88 (Suppl): 511-512.
38. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006; 70: 654-659. (Pubitemid 44215339)
39. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, CoyneDW. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract. 2007; 105: 132-138. (Pubitemid 46215207)
40. Sekkarie M. The impact of over-the-counter vitamin D supplements on vitamin D and parathyroid hormone levels in chronic kidney disease. Clin Nephrol. 2006; 65: 91-96. (Pubitemid 43224481)
41. Shah N, Bernardini J, Piraino B. Prevalence and correction of 25(OH) vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 2005; 25: 362-366. (Pubitemid 41136468)
42. Taskapan H, Ersoy FF, Passadakis SP, Tam P, Memmos ED, Katopodis PK, Ozener C, Akcicek F, Camsari T, Ates K, Ataman R, Vlachojannis JG, Dombros AN, Utas C, Akpolat T, Bozfakioglu S, Wu G, Karayaylali I, Arinsoy T, Stathakis PC. Severe vitamin D deficiency in chronic renal failure patients on peritoneal dialysis. Clin Nephrol. 2006; 66: 247-255. (Pubitemid 44541211)
43. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, Jr, Thadhani R. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005; 16: 1115-1125. (Pubitemid 41710323)
44. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG, for the Medical Directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006; 70: 1858-1865. (Pubitemid 44684819)
45. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998; 338: 777-783.
46. Wicherts IS, van Schoor NM, Boeke AJP, Visser M, Deeg DJH, Smit J, Knol DL, Lips P.VitaminDstatus predicts physical performance and its decline in older persons. J Clin Endocrinol Metab. 2007; 92: 2058-2065. (Pubitemid 46997101)
47. Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol. 2007; 27: 36-43. (Pubitemid 46364539)